NCT03481998View on ClinicalTrials.gov

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 22, 2018

Primary Completion Date

July 30, 2022

Study Completion Date

July 30, 2022

Conditions
Advanced Breast Cancer
Interventions
DRUG

SHR6390

SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

DRUG

Letrozole or anastrozole or Fulvestrant

Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease

Trial Locations (4)

450008

Henan Cancer Hospital, Zhengzhou

Unknown

Ha'erbin Tumor Hospital, Harbin

Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03481998 - A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | Biotech Hunter | Biotech Hunter